Envisagenics integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify and develop disease-specific splicing variants as therapeutics. Envisagenics’ innovative SpliceCore® technology envisions the genome as a collection of exons and not genes. Proprietary splicing regulatory modules offer the most sensitive platform to find novel disease-specific proteins as drivers of disease. All in silico discoveries and AI/machine learning designed compounds are qualified and validated experimentally in their wet lab at JLABS@NYC. The company’s first therapeutic program is in triple negative breast cancer (TNBC) to enter GLP tox studies in 2020. Envisagenics is developing a splice-switching oligonucleotide which will inhibit a novel TNBC-specific exon skipping event found in 65% of TNBC patients and which is predictive of poor survival outcome. Envisagenics is also in discussions with CROs to generate small molecule inhibitors that modulate the variant protein itself, essentially building a pipeline of targets and therapeutics within specific disease areas.